A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2013-06-01

Summary

This Phase Ib-IIa, multi-institutional, open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and feasibility of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion in combination with paclitaxel (and pertuzumab, if applicable) in patients with human epidermal growth factor receptor 2-positive (HER2-positive), locally advanced or metastatic breast cancer.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Genentech, Inc.
• Treatments: Ado-Trastuzumab Emtansine; Albumin-Bound Paclitaxel; Maytansine; Paclitaxel; Pertuzumab; Trastuzumab